PRAME and sarcoma: Treatment with DNA methyltransferase inhibitors like decitabine has been shown to upregulate PRAME in multiple tumor cell lines, including melanoma, sarcoma, and leukemia, thus improving antigen visibility to cytotoxic T cells [181].